• No results found

University of Groningen Bridging the gap Spiekman, Maroesjka

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Bridging the gap Spiekman, Maroesjka"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Bridging the gap

Spiekman, Maroesjka

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Spiekman, M. (2018). Bridging the gap: Adipose tissue-based therapy for dermal scarring. Rijksuniversiteit

Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen behorende bij het proefschrift

‘Bridging the gap: Adipose tissue-based

therapy for dermal scarring’

1. Lipofilling werkt als een tweesnijdend zwaard voor de behandeling van littekens: het verbeterd weefselvolume en reduceert littekenweefsel via immuunstimulering. Dit proefschrift

2. De behandeling voor symptomatische littekens met lipofilling vereist placebo-controlled randomized clinical trials. Dit proefschrift

3. Het gebruik van op SVF-gebaseerde therapieën, vereist standaardisering van isolatiemethoden en karakterisering van de geisoleerde SVF. Dit proefschrift 4. Adipose-derived stromal cells (ASC) inhiberen transforming growth factor beta

(TGF-β) geïnduceerde myofibroblast differentiatie in vitro via een paracrien mechanisme. Dit proefschrift

5. Gebruik van platelet rich plasma (PRP) in plaats van dierlijk serum als kweekadditief voor adipose-derived stromal cells (ASC) beïnvloed het therapeutisch effect van deze cellen op concentratie-afhankelijke wijze. Dit proefschrift

6. Toevoeging van extra adipose-derived stromal cells (ASC) of hun voorlopercellen, draagt niet bij aan lipograft survival in de fysiologische situatie. Kølle et al. 2013 7. Het geloof dat adipose-derived stromal cells (ASC) verantwoordelijk zijn voor

alle regeneratieve effecten van lipofilling, is als geloven in de tandenfee: ASC zijn immers een in vitro artefact. Rigotti et al. 2007

8. Als de huid de spiegel van de ziel is, zijn littekens meer dan een oppervlakkige aandoening.

9. Als onderzoeker dient men ervoor te waken dat ‘eerst zien, dan geloven’ niet verandert in ‘eerst geloven, dan zien’.

10. The skill set of a PhD student is significantly enriched by the company of colleagues from different nationalities and cultural backgrounds.

11. You can’t always get what you want, but if you try sometimes you just might find you get what you need. The Rolling Stones

Referenties

GERELATEERDE DOCUMENTEN

CHAPTER 7 Adipose tissue-derived stromal cells inhibit TGF-β1-induced differentiation of human dermal fibroblasts and keloid scar- derived fibroblasts in a paracrine

Furthermore, we will discuss adipose tissue-based therapy: therapeutic use of adipose tissue as well as its separate components, such as the stromal vascular fraction (SVF) or

On the other hand, studies in the field of cell-assisted lipotransfer (CAL), where lipografts are combined with ADSC in order to improve fat graft survival, there have been

In our study, significant clinical improvement in patients with symptomatic scars is accompanied by histological changes of the treated scar tissues that suggest on-going

terms (Table 2) were based on three components: (P) adipose stromal cell, adipose stem cell, stromal vascular fraction, autologous progenitor cell, or regenerative cell in

The sample size calculation is based on differences in scores of the primary measure of effect: the total score of the patient scale of the POSAS questionnaire, between the tSVF

have been applied to analyze drug metabolism 37 and served as models of drug- induced cholestatic 38 , metabolic 39 , and fibrotic 35 liver disease, but this is the first-

Decoding therapeutic roles of adipose tissue-derived stromal cells and their extracellular vesicles in liver disease..